B
Bruce E. Johnson
Researcher at Harvard University
Publications - 523
Citations - 76494
Bruce E. Johnson is an academic researcher from Harvard University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 104, co-authored 474 publications receiving 68801 citations. Previous affiliations of Bruce E. Johnson include University of Adelaide & Virginia Tech.
Papers
More filters
Journal ArticleDOI
9174 Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
J-C. Soria,Jaafar Bennouna,Natasha B. Leighl,F. Khuri,A. M. Traynor,Bruce E. Johnson,A. Kay,Normand Blais,Valentine Jehl,V. Papadimitrakopoulou +9 more
Journal ArticleDOI
Feasibility of next-generation sequencing (NGS) for squamous non-small cell lung cancer (NSCLC): Implications for the NCI LungMAP study.
Adrian G. Sacher,Lynette M. Sholl,Stacy L. Mach,Bruce E. Johnson,Peter S. Hammerman,Pasi A. Jänne,Geoffrey R. Oxnard +6 more
TL;DR: A large cohort of consecutive pts with squamous NSCLC was studied to gauge the feasibility of NGS for clinical trial arm allocation, and the rate of test utilization, assay failure, and detected genomic alterations were studied.
Journal ArticleDOI
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer
Lorena Lazo de la Vega,Hannah Comeau,S G Sallan,Alyaa Al-Ibraheemi,Hersh Gupta,Yvonne Y. Li,Harrison Tsai,Wenjun Kang,Abigail Ward,Alanna J. Church,AeRang Kim,Navin Pinto,Margaret E. Macy,Luke Maese,Amit J. Sabnis,Andrew D. Cherniack,Neal I. Lindeman,Megan E. Anderson,Tabitha Cooney,Kee Kiat Yeo,Gregory H. Reaman,Steven G. DuBois,Natalie B. Collins,Bruce E. Johnson,Katherine A. Janeway,Suzanne J. Forrest +25 more
TL;DR: The goal of this study was to determine the frequency and types of FGFR alterations in pediatric cancers to inform future clinical trial design and identify patients who would potentially be eligible for clinical trials evaluating FGFR-targeted therapy.
Journal ArticleDOI
Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade.
Benjamin Izar,Livnat Jerby-Arnon,Asaf Rotem,Parin Shah,David Liu,Gao Zhang,Bastian Schilling,Orit Rozenblatt-Rosen,Genevieve M. Boland,F. Stephen Hodi,Keith T. Flaherty,Eliezer M. Van Allen,Bruce E. Johnson,Dirk Schadendorf,Charles H. Yoon,Levi A. Garraway,Aviv Regev +16 more
TL;DR: A small number of patients with melanoma benefit from immune checkpoint blockade but most patients derive no clinical benefit, and the molecular underpinnings of ICB do not appear to change over time.